Opportunistic Infections in Transplant Patients

Introduction

• Type and dose of immunosuppressive drugs (induction agents vs. maintenance)
• Prior and current exposure to immunosuppressive therapy
• Underlying disease (diabetes, chronic renal failure)
• Pre-existing infections (CMV, EBV, HBV)
• Mucosal barrier integrity
• Neutropenia
• Anatomical disruption from surgery

Temporal Classification (Timeline of Infections)

Period 1: First Month Post-Transplant (<1 month)

• Bacteria: MRSA, VRE, gram-negative bacilli (E. coli, Pseudomonas, Klebsiella), CRE, extended-spectrum beta-lactamase (ESBL) producers
• Candida species (wound, catheter, urinary sites)
• Herpes simplex virus (HSV) - most common viral infection in this period
• Donor-derived unexpected infections: HIV, West Nile virus, rabies, LCMV, Trypanosoma cruzi

Period 2: Months 1-6 Post-Transplant (Classic Opportunistic Period)

• CMV (most important) - primary or reactivation
• EBV - risk of PTLD
• BK polyomavirus (renal allograft loss)
• Adenovirus
• RSV and other community respiratory viruses
• HBV, HCV (reactivation or new infection)

• Pneumocystis jirovecii (PCP/PJP) - if not on TMP-SMX prophylaxis
• Aspergillus spp. and other molds
• Cryptococcus neoformans
• Candida spp.

• Listeria monocytogenes
• Nocardia spp.
• Mycobacterium tuberculosis (reactivation)

• Toxoplasma gondii (esp. heart transplant, donor+/recipient-)
• Strongyloides stercoralis (hyperinfection syndrome)
• Trypanosoma cruzi, Leishmania spp. (reactivation in endemic regions)

Period 3: After 6 Months

Key Opportunistic Pathogens - In Detail

1. Cytomegalovirus (CMV)

• Sites: CNS, respiratory tract, GI tract, bone marrow, retina
• Manifestations: CMV syndrome (fever, malaise, neutropenia, thrombocytopenia) OR tissue-invasive disease (CMV pneumonitis, CMV colitis/enteritis, CMV retinitis, CMV hepatitis, meningoencephalitis, graft dysfunction)
• Risk stratification:
  • Highest risk: Donor seropositive (D+) / Recipient seronegative (R-) - primary infection
  • Intermediate: D+/R+ or D-/R+ - reactivation or superinfection
  • Lowest: D-/R-
• Indirect effects: CMV infection itself enhances immunosuppression, increasing risk of bacterial and fungal superinfections; associated with accelerated graft rejection
• Diagnosis: Quantitative PCR for CMV DNA in blood (viral load); pp65 antigenemia assay; tissue biopsy showing CMV inclusion bodies ("owl's eye" intranuclear inclusions)
• Prophylaxis:
  • Low-risk: Acyclovir
  • High-risk (D+/R-): Valganciclovir orally (drug of choice) for 3-6 months post-transplant
• Treatment: IV Ganciclovir or oral Valganciclovir (first line); Foscarnet (second line, nephrotoxic); Cidofovir (nephrotoxic, reserve); CMV immunoglobulin as adjunct; reduce immunosuppression

2. Pneumocystis jirovecii Pneumonia (PJP/PCP)

• Previously called PCP (Pneumocystis carinii pneumonia); causative organism reclassified as P. jirovecii in humans
• Manifestations: Subacute progressive dyspnea, non-productive cough, fever; bilateral interstitial infiltrates on CXR; "ground-glass" opacification on HRCT
• Diagnosis: Bronchoalveolar lavage (BAL) with Gomori methenamine silver (GMS) stain or DIF; serum beta-D-glucan elevated; PCR on BAL
• Prophylaxis (standard of care):
  • First line: TMP-SMX (single or double strength) daily or 3x/week for 6-12 months post-transplant; restart after any pulse of corticosteroids or antilymphocyte therapy
  • Alternatives (sulfa allergy): Dapsone (check G6PD first), Atovaquone, Aerosolized pentamidine
  • TMP-SMX also covers: Toxoplasma, Listeria monocytogenes, Nocardia, and reduces UTI risk in renal transplant
• Treatment: High-dose TMP-SMX IV (drug of choice); adjunctive corticosteroids if PaO2 <70 mmHg; Pentamidine for TMP-SMX intolerance

3. Epstein-Barr Virus (EBV) and PTLD

• Post-Transplant Lymphoproliferative Disorder (PTLD) is the most important complication
• Driven by EBV-driven uncontrolled B-cell proliferation in the absence of T-cell surveillance
• Risk: Highest in EBV-seronegative recipients receiving organs from EBV-seropositive donors (mismatch); pediatric recipients at highest risk
• Spectrum: Ranges from infectious mononucleosis-like illness to polymorphic PTLD to monomorphic B-cell lymphoma (most common) or T-cell lymphoma
• Sites: Bone marrow, spleen, CNS, allograft itself
• Diagnosis: EBV viral load monitoring by PCR; tissue biopsy with immunohistochemistry (CD20+ B cells)
• Treatment:
  • First step: Reduction of immunosuppression (often leads to regression in early lesions)
  • Rituximab (anti-CD20 monoclonal antibody) for CD20+ PTLD
  • Chemotherapy (CHOP-like regimens) for aggressive/monomorphic PTLD
  • CNS radiation therapy for CNS involvement
• Prophylaxis: Acyclovir or valganciclovir can reduce EBV replication

4. BK Polyomavirus (BKPyV)

• Unique to kidney transplant recipients (causes BK virus-associated nephropathy, BKVAN)
• Ubiquitous latent virus in the urinary tract; reactivates under immunosuppression
• Manifestations: Asymptomatic viruria → viremia → BKVAN → graft loss (in up to 5% of infected patients); less commonly hemorrhagic cystitis
• Diagnosis: Urine cytology (decoy cells - large cells with intranuclear inclusions); urine and plasma quantitative PCR; renal biopsy (intranuclear inclusions in tubular cells, interstitial nephritis)
• Screening: Regular plasma PCR monitoring post-transplant (monthly for first 6-12 months)
• Treatment: No proven antiviral; reduction of immunosuppression is cornerstone
  • Experimental: Cidofovir (nephrotoxic), Leflunomide (has antiviral activity via metabolite A77 1726), fluoroquinolones (reduce viral load in urine)
  • No established prophylaxis

5. Fungal Infections

• Most common in first month post-transplant
• Primarily C. albicans; increasingly non-albicans species (C. glabrata, C. krusei - fluconazole resistant)
• Prophylaxis: Fluconazole or Nystatin swish-and-swallow (especially liver, pancreas-kidney recipients)
• Treatment: Fluconazole (for susceptible strains); Echinocandins (anidulafungin, caspofungin, micafungin) for resistant strains; Amphotericin B for severe/resistant cases

• Primarily Aspergillus fumigatus; most common in lung transplant recipients
• Risk: Neutropenia, corticosteroid pulses, CMV infection, environmental exposure, single-lung transplant
• Manifestations: Pulmonary nodules with halo sign on CT, cavitation; angioinvasion with vascular thrombosis
• Prophylaxis: Voriconazole or inhaled Amphotericin B in high-risk recipients (lung transplant)
• Treatment: Voriconazole (first line); Isavuconazole; Liposomal Amphotericin B; Echinocandins (for voriconazole-refractory)

• Cryptococcus neoformans - typically 1-6 months post-transplant; can be late
• Manifestations: Subacute meningitis, meningoencephalitis, pulmonary disease, skin lesions (umbilicated papules); cryptococcemia
• Diagnosis: India ink stain, cryptococcal antigen (CrAg) in serum/CSF, fungal culture
• Treatment: Induction - Liposomal Amphotericin B + Flucytosine (2 weeks); Consolidation - Fluconazole; reduce immunosuppression; monitor ICP (serial LPs)

• Histoplasma capsulatum (Mississippi/Ohio River Valley), Coccidioides immitis (Southwestern USA/Latin America), Blastomyces, Paracoccidioides
• Can be primary or reactivation of latent disease
• Screen recipients from endemic areas; fluconazole prophylaxis for high-risk patients
• Treatment: Itraconazole (mild-moderate); Liposomal Amphotericin B (severe/disseminated)

6. Bacterial Opportunistic Infections

• Gram-positive rod; foodborne transmission
• Manifestations: Bacteremia, meningitis (CNS), febrile gastroenteritis
• Treatment: High-dose Ampicillin (± Gentamicin); TMP-SMX prophylaxis prevents this infection

• Aerobic gram-positive filamentous bacterium, weakly acid-fast
• Manifestations: Pulmonary nocardiosis (nodules, cavities, consolidation); cutaneous/subcutaneous disease; CNS nocardiosis (brain abscess)
• Treatment: TMP-SMX (high dose); Imipenem + Amikacin for severe/disseminated; duration 6-12 months
• TMP-SMX prophylaxis prevents Nocardia infection

• Reactivation of latent TB most common (1-6 months post-transplant, but can be any time)
• Risk 20-74x higher than general population
• Manifestations: Often extrapulmonary and disseminated (lymphadenopathy, hepatic, CNS, bone marrow)
• Screening: Pre-transplant TST (tuberculin skin test) or IGRA; chest X-ray
• Prophylaxis: Isoniazid (INH) 9 months for LTBI (latent TB infection) pre- or post-transplant
• Treatment: Standard 4-drug RHEZ (Rifampicin, INH, Ethambutol, Pyrazinamide) - drug interactions with calcineurin inhibitors (rifampicin is a potent CYP3A4 inducer, drastically reduces tacrolimus/cyclosporine levels)

7. Toxoplasma gondii

• Most common and severe in cardiac transplant (risk: D+/R-)
• Encephalitis is the most common manifestation; myocarditis, disseminated disease
• TMP-SMX prophylaxis prevents Toxoplasma infection
• Treatment: Pyrimethamine + Sulfadiazine + Folinic acid; TMP-SMX as alternative

8. Strongyloides stercoralis (Hyperinfection Syndrome)

• Life-threatening in immunosuppressed hosts due to hyperinfection/dissemination
• Larvae penetrate gut wall, carry enteric bacteria, causing gram-negative bacteremia/meningitis
• Screen pre-transplant in patients from endemic areas (serology)
• Treatment/Prevention: Ivermectin

Organ-Specific Infection Risks

Standard Prophylaxis Protocols

Diagnostic Approach

1. Time post-transplant - determines differential (the timeline above)
2. Net state of immunosuppression - induction agents? recent rejection treatment?
3. Type of organ transplanted - organ-specific risks
4. Epidemiologic exposure - travel, endemic fungi, TB contacts, foodborne pathogens
5. Donor/recipient serostatus - CMV, EBV, Toxo, HBV, HCV
6. Current prophylaxis - on TMP-SMX? On valganciclovir?

• Blood cultures (bacterial, fungal)
• CMV/EBV/BK PCR (quantitative)
• BAL + silver stain (PJP)
• Serology: Cryptococcal antigen, Histoplasma antigen (urine/serum)
• Skin biopsy, CSF analysis as appropriate
• High-resolution CT chest (fungal infections)

General Management Principles

• Reduce immunosuppression when life-threatening opportunistic infection occurs (critical for CMV, BK virus, fungal infections, PJP, PTLD)
• Antimicrobial prophylaxis is the cornerstone of prevention (TMP-SMX, valganciclovir, antifungals)
• Pre-transplant screening of donor and recipient for CMV, EBV, TB, HBV, HCV, HIV, Strongyloides, endemic fungi
• Immunization before transplant (live vaccines contraindicated after transplant; inactivated vaccines recommended)
• Multidisciplinary approach - transplant team + infectious disease specialist
• Restart prophylaxis after any episode of acute rejection treatment with pulse steroids or antilymphocyte agents

Recent Evidence (2024-2026)

• CMV pre-emptive therapy vs. prophylaxis: A 2025 Cochrane systematic review (PMID 39807668) compared pre-emptive treatment (treating when CMV PCR rises) vs. universal prophylaxis in solid organ transplant recipients - both strategies remain valid with prophylaxis preferred in highest-risk (D+/R-) patients.
• CMV and rejection: A 2025 systematic review and meta-analysis (PMID 41023683) confirmed that CMV infection independently contributes to acute rejection - reinforcing the importance of aggressive CMV prevention.

Summary for Examination

1. Time-based classification of infections (3 phases) with specific organisms for each
2. The concept of "net state of immunosuppression"
3. CMV as the most important opportunistic infection - D+/R- as highest risk, valganciclovir prophylaxis, ganciclovir treatment, indirect immunosuppressive effects
4. TMP-SMX prophylaxis - covers PJP, Toxoplasma, Listeria, Nocardia, UTIs
5. BK virus - unique to renal transplant, BKVAN, reduce immunosuppression (no proven antiviral)
6. EBV/PTLD - reduce immunosuppression + Rituximab
7. Organ-specific risk patterns (lung = Aspergillus; heart = Toxoplasma; kidney = BK virus)
8. Drug interactions: Rifampicin drastically lowers tacrolimus/cyclosporine levels (CYP3A4 induction)
9. Pre-transplant screening to prevent reactivation (TB-IGRA, Strongyloides serology, endemic mycosis serology, CMV/EBV status)
10. Prophylaxis reset after every rejection episode treated with pulse steroids